32 results on '"Levesque, Paul"'
Search Results
2. Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P1) Modulators: Optimization of the PK, PD, and Safety Profiles
3. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
4. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
5. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
6. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
7. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
8. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
9. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
10. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
11. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
12. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
13. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
14. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
15. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
16. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
17. Partial agonists of S1P1: Exploring side chain modifications of a bicyclic series to modulate the PK, PD, and safety profiles
18. Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor
19. Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials
20. Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders
21. Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
22. Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing
23. Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent IKur Inhibitor
24. Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)
25. Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials
26. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311)
27. The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
28. Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
29. Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)
30. Correction to Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone As a Potent and Selective IKur Inhibitor
31. Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone As a Potent and Selective IKur Inhibitor
32. Design and Synthesis of 4-Substituted Benzamides as Potent, Selective, and Orally Bioavailable IKs Blockers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.